Based on the Interpace Biosciences Inc stock forecast from 0 analysts, the average analyst target price for Interpace Biosciences Inc is not available over the next 12 months. Interpace Biosciences Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Interpace Biosciences Inc is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Interpace Biosciences Inc’s stock price was USD 1.25. Interpace Biosciences Inc’s stock price has changed by +1.63% over the past week, +101.61% over the past month and +29.40% over the last year.
No recent analyst target price found for Interpace Biosciences Inc
No recent average analyst rating found for Interpace Biosciences Inc
Company Overview Interpace Biosciences Inc
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company primarily serves physicians, cancer center, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Read Less
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosi...Read More
Frequently Asked Questions About Interpace Biosciences Inc (IDXG) Stock
Stock Target Advisor's fundamental analysis for Interpace Biosciences Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on IDXG's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on IDXG's stock to indicate what its average analyst target is.
IDXG stock's Price/Earning ratio is 0.82.
Our analysis grades IDXG stock's Price / Earning ratio at C. This means that IDXG stock's Price/Earning ratio is above 25% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this IDXG may be undervalued for its sector.
The last closing price of IDXG's stock was USD 1.25.
The most recent market capitalization for IDXG is USD 3.96M.
Unfortunately we do not have enough analyst data on IDXG's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Interpace Biosciences Inc's stock.
As per our most recent records Interpace Biosciences Inc has 108 Employees.
Interpace Biosciences Inc's registered address is Waterview Plaza, Parsippany, NJ, United States, 07054.
You can get more information about it from Interpace Biosciences Inc's website at https://www.interpace.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Interpace Biosciences Inc (IDXG) Stock
Stock Target Advisor's fundamental analysis for Interpace Biosciences Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on IDXG's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on IDXG's stock to indicate what its average analyst target is.
IDXG stock's Price/Earning ratio is 0.82.
Our analysis grades IDXG stock's Price / Earning ratio at C. This means that IDXG stock's Price/Earning ratio is above 25% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this IDXG may be undervalued for its sector.
The last closing price of IDXG's stock was USD 1.25.
The most recent market capitalization for IDXG is USD 3.96M.
Unfortunately we do not have enough analyst data on IDXG's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Interpace Biosciences Inc's stock.
As per our most recent records Interpace Biosciences Inc has 108 Employees.
Interpace Biosciences Inc's registered address is Waterview Plaza, Parsippany, NJ, United States, 07054.
You can get more information about it from Interpace Biosciences Inc's website at https://www.interpace.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IDXG !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
